Related Experiment Video

Updated: Aug 9, 2026

A Primary Neuron Culture System for the Study of Herpes Simplex Virus Latency and Reactivation
12:22

A Primary Neuron Culture System for the Study of Herpes Simplex Virus Latency and Reactivation

Published on: April 2, 2012

Herpes simplex virus 1 (HSV-1) for cancer treatment

Y Shen1, J Nemunaitis

  • 1Mary Crowley Medical Research Center, Dallas, TX 75201, USA.

Cancer Gene Therapy
|April 11, 2006
PubMed

Insights

Herpes simplex virus type 1 (HSV-1) shows promise as a vector for gene therapy and oncolytic virotherapy in cancer treatment. Genetic modifications enhance its potential for targeted cancer cell destruction and gene delivery.

Area of Science:

  • Oncology
  • Virology
  • Gene Therapy

Background:

  • Cancer is a leading cause of death, necessitating novel therapeutic strategies.
  • Gene therapies and oncolytic virotherapies are emerging as promising cancer treatments.
  • Herpes simplex virus type 1 (HSV-1) possesses characteristics suitable for developing these therapies.

Purpose of the Study:

  • To review the biology of HSV-1.
  • To examine strategies for genetically modifying HSV-1 for cancer therapy.
  • To discuss the preclinical and clinical outcomes of HSV-1-derived vectors in cancer treatment.

Main Methods:

  • Review of existing literature on HSV-1 biology and genetic modification techniques.
  • Analysis of preclinical studies involving HSV-1 vectors in cancer models.
  • Evaluation of clinical trial data for HSV-1-based cancer therapies.

Main Results:

  • HSV-1 is highly infectious and cytotoxic, making it an efficient delivery vector for therapeutic genes.
  • Genetic modifications can enhance HSV-1's selectivity and oncolytic potential.
  • Preclinical and clinical studies demonstrate the feasibility of HSV-1 vectors in cancer treatment.

Conclusions:

  • HSV-1 is a versatile platform for developing advanced cancer therapies, including gene therapy and oncolytic virotherapy.
  • Further research and clinical trials are warranted to optimize HSV-1-based treatments for various cancers.
  • Genetic engineering of HSV-1 offers a promising avenue for targeted and effective cancer intervention.

More Related Videos

Recurrent Herpetic Stromal Keratitis in Mice, a Model for Studying Human HSK07:27

Recurrent Herpetic Stromal Keratitis in Mice, a Model for Studying Human HSK

Published on: December 18, 2012

Ex Vivo Infection of Murine Epidermis with Herpes Simplex Virus Type 111:56

Ex Vivo Infection of Murine Epidermis with Herpes Simplex Virus Type 1

Published on: August 24, 2015

Related Concept Videos

Herpes01:28

Herpes

Herpes simplex type 1 (HSV‑1) is a widespread pathogen responsible for orolabial lesions. It is an enveloped, double-stranded DNA (dsDNA) virus belonging to the family Herpesviridae. Once the virus infects a host cell, its double‑stranded DNA genome is delivered into the nucleus, where a coordinated cascade of immediate‑early, early, and late gene expression directs viral DNA replication, structural protein synthesis, and virion assembly. After primary infection of epithelial cells, HSV-1...
Genital Herpes01:23

Genital Herpes

Genital herpes is a sexually transmitted infection primarily caused by herpes simplex virus type 2 (HSV-2), though herpes simplex virus type 1 (HSV-1) is increasingly implicated in genital infections, particularly among younger populations. Transmission occurs mainly through sexual contact, with asymptomatic viral shedding serving as a major route of spread. This characteristic makes HSV-2 difficult to control at a population level, as individuals may unknowingly transmit the virus even in the...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Chickenpox01:20

Chickenpox

Chickenpox is an acute, highly contagious disease caused by the varicella-zoster virus (VZV), a double-stranded DNA virus belonging to the Herpesviridae family. Its transmission occurs primarily through the inhalation of respiratory droplets or direct contact with vesicular fluid from skin lesions. The incubation period typically ranges from 10 to 21 days, during which the virus replicates and disseminates through sequential phases within the host. Although generally self-limiting in children,...